Discover how mini-proteins deliver targeted radiation to Nectin-4 expressing tumor cells, sparing healthy tissues and offering new hope for cancer...
Vous n'êtes pas connecté
Cancer remains one of the most challenging diseases to treat due to its complexity and tendency to metastasize (spread into or invade, nearby tissues or distant places in the body to form new tumors). Traditional therapies, such as chemotherapy and radiation, often face limitations like non-specific targeting and severe side effects. In response, researchers are turning to innovative approaches that combine multiple therapeutic modalities to address these issues. This study explores a cutting-edge solution involving CNHs to create a multimodal cancer phototheranostic platform integrating photothermal therapy (PTT), immunotherapy, and chemotherapy.
Discover how mini-proteins deliver targeted radiation to Nectin-4 expressing tumor cells, sparing healthy tissues and offering new hope for cancer...
Despite significant advancements in cancer treatment, drug resistance remains a persistent challenge. Cancer cells can often develop resistance to...
A team of scientists has uncovered a mechanism by which ovarian cancer tumors evade immunotherapy. They've also pinpointed a potential drug target...
Researchers from The University of Texas MD Anderson Cancer Centre, USA, demonstrated that anti-PD-L1 immunotherapy in combination with...
Mini-proteins are engineered protein capsule, bcapable of delivering targeted radiation dose directly to tumor cells expressing Nectin-4/b. ...
Recently, a collaborative research team led by Prof. Wang Hui and Prof. Qian Junchao from the Hefei Institutes of Physical Science of the Chinese...
A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response to immunotherapy in...
Mohali’s Homi Bhabha Cancer Hospital and Research Centre (HBCHRC) sees patients from Punjab, Haryana, Himachal Pradesh, Jammu & Kashmir and even...
It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy,...
HER2-targeted therapies, originally developed for breast cancer, may also benefit patients with rare bile duct cancer and HER2-mutated breast...